Scotia Holdings Plc.

Efamol Limited

Bioscience Technology Investment Holdings Limited

Other

Mehar S Manku

David F Horrobin

Philip Knowles

Austin McMordie

Peter Redden

Andrea Pitt

Paul Bradley

Paul Andrew Wakefield

John C Stewart

Stephen C Cunnane

David C Rice

Yung S Huang

A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).

Compounds for PDT

New porphyrins and chlorins including bacteriochlorins, for photodynamic therapy.

Porphyrins and related compounds

A nutritional, cosmetic or pharmaceutical formulation comprising esters of polyethylene glycol in which the polyethylene glycol chain is terminated at one end by a polyunsaturated fatty acyl group, preferably C -C and at the other end by a C -C alkyl group, preferably a methyl group.

Polyethylene glycol esters of polyunsaturated fatty acids

1,3-propane diol esters and ethers and methods for their use in drug delivery

Compounds of structure (I), and when for use in therapy: where R,is an acyl group derived from a C,fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or columbinic acid, or parinaric acid and R,is as R,the same or different, or any other nutrient, drug or other bioactive residue released as the active in the body and R,is either hydrogen, fully hydrocarbon, or containing heteroatoms, preferably an alkyl group particularly a C,-C,alkyl group.

Fatty acid esters as bioactive compounds

Optimum conditions for prostaglandin synthesis are provided by internally administering an ascorbic-6-acid ester of gamma-linolenic acid or an ascorbic-6-acid ester of dihomo-gamma-linolenic acid.

Methods of treatment using ascorbyl gamma linolenic acid or ascorbyl dihomo-gamma-linolenic acid

Nicotinic acid esters and pharmaceutical compositions containing them

N-alkylpolyhydroxyamine salts of polyunsaturated fatty acids

Triglycerides with at least two different acids chosen from 6-desaturated essential fatty acids and oleic acid, useful in nutrition and in medicine.

Triglycerides

Ascorbyl-GLA or Ascorbyl-DGLA in medicaments for treatment of asthma and other disorders.

Fatty acid derivatives

A triglyceride for use in therapy or as a nutritional supplement, or a composition containing a triglyceride, wherein the triglyceride comprises a fatty acid selected from gamma-linolenic acid and the n-6 EPAs naturally derived therefrom and stearidonic acid and the n-3 EFAs naturally derived therefrom, forming a triple ester with glycerol or alternatively forming a double ester in which the other esterifying acide is a single residue of linoleic acid, with the proviso that the di-gammalinolenoyl-mono-linoleoyl glyceride if selected is used as a preparation containing more than 20% by weight thereof.

Triglycerides of fatty acids

A natural vitamin E preparation, i.e. vitamin E extracted from natural sources, comprising one or more of the alpha-, beta-, gamma- and delta-tocopherol forms, either as the tocopherol itself, or as a derivative, such as the acetate, in which the total concentration of Wendt PAHs is less than 100 ppb.

Tocopherols

A phospholipid comprising two different unsaturated fatty acids, the fatty acids being selected from the twelve n-6 and n-3 essential fatty acids, oleic acid, parinaric acid and combinic acid.

Formulations containing unsaturated fatty acids

Methods of influencing the 1-series/2-series PG balance in the body by administering a composition containing .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid and assimilable copper compounds optionally with a diluent or carrier, the acids being as such or as derivatives convertible in the body thereto. The amounts of the acids or derivatives are 0.2 to 10 g (calculated as .gamma.-linolenic acid) and of copper compounds are 0.1 to 100 mg (calculated as copper).

Methods of increasing 1-series PGs in the body

Gamma-linolenic acid or dihomo-gamma-linolenic acid for use in the reduction or prevention of gastro-intestinal bleeding and other side effects shown by NSAIDs when administered on a continuing basis, including use in allowing said administration to be replaced by administration of said acid alone in arthritis and other conditions without exacerbation of symptoms.

Growing community of inventors

Carlisle, United Kingdom

Mehar S Manku